Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Codexis, Inc.NASDAQ: CDXS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $3.31M rose 21.2% year over year, ahead of the -11.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -37.4% a year.

Context

  • Cost of revenue amounted to 13.3% of revenue in FY2025, down 14.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.2% holds above the trailing-twelve-month pace of -11.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.31M-1.5% QoQ
Last fiscal yearDec 2025
$9.34M-42.7% YoY
LTMMar 2026
$12.54M-11.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.2%——
1 year-42.7%——
3-year CAGR-37.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
9.34M USD
Year-over-year change
-42.7%
4-year CAGR
-19.5%

Cost of Revenue vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.5% is the 2nd highest of 6, against a peer median of -40.6%.
  • Cost of revenue amounts to 16.1% of revenue for CDXS, versus a peer median of 6.6%.
CDXS Competitors
Cost of Revenue for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$18.66M USD——64.5%
CDXSCodexis, Inc.LTM Mar 2026$12.54M USD-11.5%-37.4%16.1%
IVVDInvivyd, Inc.LTM Mar 2026$4.46M USD+81.8%—8.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$1.8M USD-69.3%—5.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$1.57M USD-13.9%+58.2%80.5%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$823K USD-40.6%-64.8%27.8%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
TARAProtara Therapeutics, Inc.LTM Mar 2026$90K USD———
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD—-14.4%0.0%
Peer median (excluding CDXS) —-40.6%-14.4%6.6%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.